|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastric autoimmune disorders in patients with chronic hepatitis C before,during and after interferon-alpha therapy显示文摘AIM: To explore the prevalence of autoimmune gastritis in chronic hepatitis C virus (HCV) patients and the influence of α-intefferon (IFN) treatment on autoimmune gastritis.METHODS: We performed a prospective study on 189patients with positive anti-HCV and viral RNA enrolled in a 12-month IFN protocol. We evaluated: a) the baseline prevalence of autoimmune gastritis, b) the impact of IFN treatment on development of biochemical signs of autoimmune gastritis (at 3, 6 and 12 months), c) the evolution after IFN withdrawal (12 months) in terms of anti-gastric-parietal-cell antibodies (APCA), gastrin, anti-thyroid, and anti-non-organ-specific antibodies.RESULTS: APCA positivity and 3-fold gastrin levels were detected in 3 (1.6 %) and 9 (5 %) patients, respectively, at baseline, in 25 (13 %) and 31 (16 %) patients at the end of treatment (both P<0.001, vs baseline), and in 7 (4 %) and 14 (7 %) patients 12 months after withdrawal (P=0.002and ,P=0.01 respectively, vs baseline; P=not significant vs end of treatment). The development of autoimmune gastritis was strictly associated with the presence of autoimmune thyroiditis (P =0.0001), no relationship was found with other markers of autoimmunity.CONCLUSION: In HCV patients, IFN frequently precipitates latent autoimmune gastritis, particularly in females. Following our 12-month protocol, the phenomenon generally regressed. Since APCA positivity and high gastrin levels are associated with the presence of antithyroid antibodies,development of autoimmune thyroiditis during IFN treatment may provide a surrogate preliminary indicator of possible autoimmune gastritis to limit the need for invasive examinations. | Carlo Fabbri M.Francesca Jaboli Silvia Giovanelli Francesco Azzaroli Alessandro Pezzoli Esterita Accogli Stefania Liva Giovanni Nigro Anna Miracolo Davide Festi Antonio Colecchia Marco Montagnani Enrico Roda Giuseppe Mazzella | 2003 | World Journal of Gastroenterology2003，9，7： | 3 |
| 2 | Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status显示文摘 | Franco Trevisani Paola Emanuela D’Intino Antonio Maria Morselli-Labate Giuseppe Mazzella Esterita Accogli Paolo Caraceni Marco Domenicali Stefania De Notariis Enrico Roda Mauro Bernardi | 2001 | Journal of Hepatology2001，，4： | 3 |
| 3 | Rate, causes, and impact on patient outcome of implantahle device complications re- quiring surgical revision: large population survey from two centres in Italy 显示文摘 | Palmisano P Accogli M Zaccaria M | 2013 | Europace2013，15，4： | 1 |
| 4 | Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status显示文摘 | Franco Trevisani Paola Emanuela D’Intino Antonio Maria Morselli-Labate Giuseppe Mazzella Esterita Accogli Paolo Caraceni Marco Domenicali Stefania De Notariis Enrico Roda Mauro Bernardi | 2001 | Journal of Hepatology2001，，4： | 1 |
| 5 | Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis显示文摘 | Giuseppe Mazzella Esterita Accogli Sandra Sottili Davide Festi Monica Orsini Antonio Salzetta Vieri Novelli Antonio Cipolla Carlo Fabbri Alessandro Pezzoli Enrico Roda | 1996 | Journal of Hepatology1996，，2： | 1 |
| 6 | Emergence of Escherichia coli ST131 sub-clone H30 producing VIM-1 and KPC-3 carbapene- mases, Italy显示文摘 | Accogli M Giani T Monaco M | 2014 | J Antimicrob Chemother2014，69，8： | 1 |
| 7 | Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis显示文摘 | Giuseppe Mazzella Esterita Accogli Sandra Sottili Davide Festi Monica Orsini Antonio Salzetta Vieri Novelli Antonio Cipolla Carlo Fabbri Alessandro Pezzoli Enrico Roda | 1996 | Journal of Hepatology1996，，2： | 1 |
| 8 | Serum-specific IgE and allergen immunotherapy in allergic children 显示文摘 | Tosca M Silvestri M Accogli A | 2014 | Immunotherapy2014，6，1： | 1 |
| 9 | Rate,causes,and impact on patient outcome of implantable device complications requiring surgical revision:large population survey from two centres in Italy显示文摘 | Palmisano P Accogli M Zaccaria M | 2013 | Europace2013，15，4： | 1 |
| 10 | Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis显示文摘 | Mazzella G Accogli E Sottili S | 1996 | J Hepatol1996，24，2： | 1 |
| 11 | Microsurgery for lymphedema: clinical research and long-term results 显示文摘 | Campisi C Bellini C Accogli S | 2010 | Microsurgery2010，30，4： | 1 |
| 12 | Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: A prospective study on patients with HCV related cirrhosis显示文摘AIM: To determine the role of interferon (IFN) with or without ribavirin in preventing or delaying hepatocellular carcinoma (HCC) development in patients with hepatitis C virus (HCV) related cirrhosis. Data on the preventive effect of IFN plus ribavirin treatment are lacking.METHODS: A total of 101 patients (62 males and 39 females, mean age 55.1:1:1.4 years) with histologically proven HCV related liver cirrhosis plus compatible biochemistry and ultrasonography were enrolled in the study. Biochemistry and ultrasonography were performed every 6 too. Ultrasound guided liver biopsy was performed on all detected focal lesions. Follow-up lasted for 5 years. Cellular proliferation, evaluated by measuring Ag-NOR proteins in hepatocytes nuclei, was expressed as AgNOR-Proliferative index (AgNOR-PI) (cut-off = 2.5). Forty-one patients (27 males, 14 females) were only followed up after the end of an yearly treatment with IFN-alpha2b (old treatment control group = OTCG). Sixty naive patients were stratified according to sex and AgNOR-PI and then randomized in two groups: 30 were treated with IFN-alpha2b + ribavirin (treatment group=TG), the remaining were not treated (control group=CG). Nonresponders (NR) or relapsers in the TG received further IFN/ribavirin treatments after a 6 mo of withdrawal. RESULTS: AgNOR-PI was significantly lowered by IFN (P<0.001). HCC incidence was higher in patients with AgNOR-PI>2.5 (26% vs3%, P<0.01). Two NR in the OTCG, none in the TG and 9 patients in the CG developed HCC during follow-up. The Kaplan-Mayer survival curves showed statistically significant differences both between OTCG and CG (P<0.004) and between TG and CG (P<0.003). CONCLUSION: IFN/ribavirin treatment associated with retreatment courses of NR seems to produce the best results in terms of HCC prevention. AgNOR-PI is a useful marker of possible HCC development. | Francesco Azzaroli Esterita Accogli Giovanni Nigro Davide Trerè Silvia Giovanelli Anna Miracolo Francesca Lodato Marco Montagnani Mariarosa Tamé Antonio Cloecchia Constance Mwangemi Davide Festi Enrico Roda Massimo Derenzini Giuseppe Mazzella | 2004 | World Journal of Gastroenterology2004，10，21： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员